Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery
Shubh K Patel1, Miriam S Badross2, Nitish K Dhingra3
1Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Insights
Elevated lipoprotein(a) levels increase risks after coronary artery bypass grafting (CABG). Routine measurement and emerging therapies may improve outcomes for patients with coronary artery disease (CAD).
Area of Science:
- Cardiology
- Vascular Surgery
- Clinical Biochemistry
Background:
- Coronary artery bypass grafting (CABG) is vital for coronary artery disease (CAD) management.
- Optimizing modifiable risk factors pre-CABG improves surgical outcomes.
- Lipoprotein(a) [Lp(a)] is increasingly recognized for its role in ischemic cardiovascular disease and CABG outcomes.
Purpose of the Study:
- To review the role of Lp(a) in CAD pathogenesis and CABG outcomes.
- To discuss perioperative management strategies for Lp(a) in CABG patients.
Main Methods:
- A comprehensive literature search of PubMed/MEDLINE up to March 2024.
- Inclusion of studies evaluating Lp(a) in relation to CABG surgery and CAD outcomes.
Main Results:
- Lipoprotein(a) is a causal, independent risk factor for CAD development.
- Higher Lp(a) levels correlate with adverse post-CABG events, including graft occlusion and major adverse cardiovascular events.
- Emerging Lp(a)-lowering therapies show potential for improving prognosis after CABG.
Conclusions:
- Lp(a) levels can stratify risk and guide perioperative management in patients undergoing CABG.
- Routine Lp(a) measurement is recommended for all CABG candidates.
- Further research on Lp(a)-lowering agents in cardiac surgery subcohorts is needed to confirm their efficacy in improving CABG outcomes.
Background:
Coronary artery bypass grafting (CABG) remains a cornerstone in the management of coronary artery disease (CAD). In nonurgent surgical revascularization cases, preoperative optimization of modifiable risk factors can improve outcomes. There is increasing interest in the relationship between lipoprotein(a) levels and the risk for ischemic cardiovascular disease, particularly how CABG outcomes are in turn affected. This review highlights the role of lipoprotein(a) in the pathogenesis of CAD and CABG outcomes and discusses future directions for its optimal management in the perioperative period.
Methods:
The PubMed/MEDLINE database was reviewed until March 2024 to capture publications that evaluated and/or described the relationship between lipoprotein(a) and CABG surgery or CAD outcomes.
Results:
The available literature supports lipoprotein(a) as a causal and independent risk factor for the pathogenesis of CAD. Elevated lipoprotein(a) levels are associated with an increased risk of adverse post-CABG outcomes, including graft occlusion incidence and major adverse cardiovascular events. Genetic variations influencing lipoprotein(a) levels play a role in disease progression and surgical outcomes. Several therapies aimed at reducing lipoprotein(a) levels, currently in phase III clinical trials, show promise for improving the prognosis after CABG.
Conclusions:
Among individuals undergoing surgical revascularization for CAD, lipoprotein(a) levels may help define risk and inform best practices for perioperative management. We advocate for the routine measurement of lipoprotein(a) in all patients undergoing CABG. Emerging lipoprotein(a)-lowering agents show promise for secondary prevention of cardiac events, although dedicated analyses in cardiac surgical subcohorts will be important to evaluate their role in improving CABG outcomes.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Peripheral Artery Disease I: Introduction


